BriaCell Therapeutics Corp (BCTX) with a beta value of 1.32 appears to be a promising investment opportunity.

BriaCell Therapeutics Corp (NASDAQ: BCTX) on Tuesday, plunged -9.46% from the previous trading day, before settling in for the closing price of $1.48. Within the past 52 weeks, BCTX’s price has moved between $1.27 and $7.59.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The company achieved an average annual earnings per share of -6.92%. With a float of $15.46 million, this company’s outstanding shares have now reached $15.98 million.

Considering the fact that the conglomerate employs 12 people, you should pay attention to its efficiency factor.

BriaCell Therapeutics Corp (BCTX) Breakdown of a Key Holders of the stock

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of BriaCell Therapeutics Corp is 15.45%, while institutional ownership is 12.04%. The most recent insider transaction that took place on May 14 ’24, was worth 2,000,001. In this transaction Director of this company bought 902,935 shares at a rate of $2.21, taking the stock ownership to the 2,542,935 shares.

BriaCell Therapeutics Corp (BCTX) Recent Fiscal highlights

As on 4/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.15 earnings per share (EPS) for the period topping the consensus outlook (set at -0.39) by 0.24. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -6.92% per share during the next fiscal year.

BriaCell Therapeutics Corp (NASDAQ: BCTX) Trading Performance Indicators

BriaCell Therapeutics Corp (BCTX) is currently performing well based on its current performance indicators. A quick ratio of 0.82 was reported for the most recent quarter.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.25, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.00 in one year’s time.

Technical Analysis of BriaCell Therapeutics Corp (BCTX)

Compared to the last year’s volume of 0.11 million, its volume of 59900.0 showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 38.37%. Additionally, its Average True Range was 0.17.

During the past 100 days, BriaCell Therapeutics Corp’s (BCTX) raw stochastic average was set at 2.27%, which indicates a significant decrease from 14.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.72% in the past 14 days, which was lower than the 93.04% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.8818, while its 200-day Moving Average is $3.7940. Nevertheless, the first resistance level for the watch stands at $1.4700 in the near term. At $1.6000, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.6900. If the price goes on to break the first support level at $1.2500, it is likely to go to the next support level at $1.1600. Now, if the price goes above the second support level, the third support stands at $1.0300.

BriaCell Therapeutics Corp (NASDAQ: BCTX) Key Stats

Market capitalization of the company is 24.50 million based on 18,285K outstanding shares. Right now, sales total 0 K and income totals -20,300 K. The company made 0 K in profit during its latest quarter, and 1,720 K in sales during its previous quarter.